By Fineline Cube Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply, distribution, and co-promotion agreement with Merck & Co., Inc. (MSD, NYSE: MRK). Under the revised deal, Zhifei retains exclusive rights to import, distribute, co-promote, and sell key Merck vaccines in mainland China, including Gardasil 9 (9-valent HPV), Rotateq (pentavalent rotavirus), and Pneumovax 23 (23-valent pneumococcal polysaccharide vaccine) under the Merck Sharp & Dohme trademark.
Key Terms of the Revised Agreement
| Feature | Change vs. Prior Agreements |
|---|---|
| Purchase Commitment | No fixed base volume—replaced with rolling, demand-based procurement |
| Supply Planning | Annual purchase plans to be jointly confirmed based on anticipated market demand and actual vaccination rates |
| Product Portfolio | Expanded to include three core Merck vaccines, reinforcing Zhifei’s position as Merck’s primary China vaccine partner |
| Commercial Flexibility | Greater alignment with real-world uptake, reducing inventory risk and improving supply chain responsiveness |
This marks a strategic evolution from the rigid, multi-billion-dollar fixed-volume contracts of the past—most notably the RMB 18.02 billion (USD 2.67B) 2018–2021 deal and the USD 14.8 billion 2023 revision—toward a more agile, market-responsive partnership.
Historical Context & Partnership Milestones
- 2011: Initial partnership formed; Zhifei appointed Merck’s exclusive vaccine distributor in mainland China.
- 2017: Four-valent Gardasil approved in China after six-year regulatory review.
- 2018: Gardasil 9 received conditional approval; same year, parties signed RMB 18.02B supply pact.
- 2023: Agreement scaled up to USD 14.8B, reflecting surging HPV vaccine demand.
- 2026: Transition to flexible, rolling procurement model signals maturity of China’s vaccine market and confidence in sustained demand.
Strategic Implications
- For Zhifei: Solidifies dominance in China’s premium vaccine import segment and ensures continued access to Merck’s high-margin, high-demand products.
- For Merck: Maintains strong commercial foothold in China—the world’s second-largest pharmaceutical market—without bearing local distribution complexity.
- Market Impact: The shift away from fixed quotas may ease past supply-demand imbalances that led to shortages (e.g., Gardasil waiting lists) or overstock risks.
Market Outlook
- HPV Vaccination Gap: Only ~10% of eligible Chinese women have completed HPV vaccination; significant upside remains for Gardasil 9.
- Public Health Push: China’s “Healthy China 2030” initiative prioritizes cancer prevention, supporting long-term vaccine adoption.
- Revenue Visibility: While near-term revenue is less predictable without fixed volumes, the demand-linked model better reflects sustainable market growth.
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance, market demand, and partnership dynamics. Actual results may vary due to regulatory changes, public health policies, and competitive pressures.-Fineline Info & Tech